MAGNOLIA, Texas, Feb. 4, 2026 — Stratus^® Medical, a company focused on advancing radiofrequency (RF) ablation treatment for chronic pain, announced a $10 million Series B financing. The financing was led by Wasatch Health Partners, a healthcare-focused investment firm pursuing growth equity and lower middle-market buyout strategies. Wasatch Health Partners invested through its Growth Fund and previously provided a $25 million convertible debt facility through its Structured Capital platform.

The proceeds from the Series B financing will be used to complete development of the Stratus Medical RF Generator and neurovasis^™ basivertebral nerve ablation (BVNA) technology, expand and protect the company’s valuable patent portfolio, and fund a clinical study. These high-potential technologies will allow Stratus Medical to better serve its rapidly growing customer base while leveraging the proven and patented NIMBUS^® RF Multitined Expandable Electrode (Nimbus) design.

Vertebrogenic low back pain develops when the vertebral endplates in the spine become damaged, often as a result of progressive degeneration over time. Current treatment options include medications, physical therapy, and basivertebral nerve ablation (BVNA). It is estimated that more than five million people in the United States suffer from vertebrogenic back pain.

The Stratus Medical RF Generator and neurovasis BVNA technologies are under development and have not been submitted, evaluated, or cleared by the FDA.

Luke Larsen, Vice President at Wasatch Health Partners, said, “We are pleased to expand our partnership with Stratus Medical. The company has demonstrated strong execution, consistent revenue growth, and meaningful progress across technology development and clinical initiatives. We believe the management team is well positioned to continue building on this momentum.”

Bret Boudousquie, CEO of Stratus Medical, commented, “We appreciate the long-term relationship with Wasatch Health Partners and their continued belief in our mission to help chronic pain patients by advancing RF technology. Stratus Medical is proud to work with outstanding physicians, hospitals, and ASCs, and we are anxious to deliver additional value with our future RF technologies that this financing enables us to complete.”

Doug Beall, MD, Director of Interventional Radiology, Clinical Radiology of Oklahoma, commented, “I started using Nimbus in 2020 for radiofrequency ablation pain treatments due to its larger ablation zone and ease of use. In 2022, I started providing scientific input on the neurovasis project. In 2024, my colleagues and I published the first scientific article describing the neurovasis BVNA technique utilizing CT reconstruction to assess device placement. This technology builds on the Nimbus multitined design and has the potential to offer faster, easier-to-use RF treatments and cost reductions for hospitals and ASCs.”

About Stratus Medical
Stratus Medical is a medical device company focused on reducing pain and improving the quality of life for chronic pain patients through innovation. The Company has been recognized for revenue growth and innovation by Deloitte Technology Fast 500, Pepperdine Most Fundable Companies, and The Houston Business Journal. Nimbus has rapidly gained market share in the US and other countries based on ease of use, reduced procedure times, and its large-volume lesion designed to provide sustained pain relief. Stratus Medical is headquartered in Magnolia, Texas.

About Wasatch Health Partners
Wasatch Health Partners is a healthcare-focused investment firm investing in medical device, life science, and outsourced medtech, and pharmaceutical services companies through growth equity, lower middle-market buyouts, and structured capital strategies. The firm is headquartered in Salt Lake City, Utah.

Media Contact
Cody Jorgensen
Marketing Communications
Stratus Medical
346-703-0642
[email protected]
https://stratusmedical.com 

SOURCE Stratus Medical

MIDDLETON, Wis., Feb. 3, 2026 — Imbed Biosciences, a leader in advanced synthetic antimicrobial and tissue regeneration solutions, today announced a strategic investment from BioLab Holdings Inc. This investment is set to significantly expand Imbed Biosciences’ reach within the US market, particularly in the MD office setting, and accelerate the development of its proprietary SAM^™ Antimicrobial Technology platform to minimize wound care complications.

To learn more about Imbed Biosciences and its innovative wound care technologies, please visit www.imbedbio.com.

“The strategic investment from BioLab Holdings marks a pivotal moment for Imbed Biosciences,” said Terry Bromley, Imbed Biosciences CEO, “significantly expanding our reach of within the critical U.S. market, especially in the MD Office setting, and empowering us to further advance our technology platform, unique in its ability to integrate multiple therapeutic agents into a one-product solution to address unmet needs in wound care.”

Advancing Wound Care Solutions

This strategic investment enables Imbed Biosciences to further expand its product platform, designed to help achieve zero wound‑care complications, supported by a growing body of compelling clinical evidence. Imbed Biosciences holds a unique position in the skin substitute market, offering the only fully synthetic and antimicrobial solution of its kind. The investment from BioLab is centered around Imbed’s Microlyte^® product, which is focused on chronic wound indications and engineered for effective bioburden reduction as well as cell proliferation during the crucial “scaffolding” phase of healing.

“At BioLab, we invest in platforms that have the potential to elevate how clinicians approach wound care,” said Jaime Leija, president and CEO of BioLab Holdings. “Imbed’s SAM^™ technology represents a combination of scientific rigor, practical design, and long‑term scalability. We see tremendous opportunity to support its adoption in physician office settings, while helping accelerate solutions that simplify care delivery and improve outcomes for patients.”

The investment underscores a shared commitment to advancing patient outcomes in wound care through innovative, effective solutions. For details on BioLab Holdings Inc.’s announcement, refer to their press release.

Media Contact: Hillary Rush, VP Marketing, Email: [email protected]

About Imbed Biosciences
Imbed Biosciences is a privately held medical device company advancing the next generation of wound care through its SAM^™ Antimicrobial Technology. The company’s platform incorporates multiple therapeutic agents into ultra‑thin, biocompatible matrices that support skin regeneration in both chronic and acute wounds. Imbed’s expanding product portfolio is engineered to reduce infection risk, alleviate pain, and promote healing across the entire wound‑care continuum.

About BioLab Holdings, Inc.
BioLab Holdings, Inc. is a Phoenix-based medical manufacturer specializing in wound protection. Its products—including Membrane Wrap – Lite ^™ and Membrane Wrap ^™ use human tissue allograft derived from amniotic membrane to provide structural tissue for wound protection. BioLab’s mission is optimize the standard of care through innovations grounded in science, compassion, and collaboration.

SOURCE Imbed Biosciences

Based on the tactics of U.S. intelligence agencies, GenLogs applies AI to a nationwide sensor network, satellites, and other data streams to drive greater efficiency and defend against crimes

ARLINGTON, Va., Feb. 3, 2026 — GenLogs, whose innovative Truck Intelligence™ technology is being deployed across industries to make supply chains safer and stronger, announced it has closed $60 million in Series B funding. The round was led by Battery Ventures with participation by IVP, Cathay Innovation, and 9Yards, as well as existing investors Venrock, Steel Atlas, HOF Capital, TitletownTech, and Autotech Ventures. GenLogs previously raised $21 million in Seed and Series A funding.

The company will use the new funds to continue building out its core platform—powered by its privacy-enabled network of roadside sensors—and extend capabilities to shippers, insurers, governments, and financial institutions. Current customers include Fortune 500 companies across these sectors, including logistics and supply-chain expert J.B. Hunt, trucking company Werner Enterprises, insurer AIPSO, and Jacksonville Port Authority (JAXPORT).

“The trillion-dollar trucking industry links every sector of our economy, but it is highly fragmented in its composition and still analog in its operations,” said Ryan Joyce, a veteran former CIA officer who co-founded GenLogs in 2023 and serves as CEO. “GenLogs is applying many aspects of the U.S. intelligence community’s playbook to drive total visibility in the trucking industry, resulting in more efficiency, better pricing, and protection against fraud and $35 billion in annual cargo theft.”

To do this, GenLogs leverages trillions of data points collected from millions of satellites and sensors—including cameras that sit on roadside infrastructure and ports nationwide that capture real-time data on trucks. The company then applies proprietary AI to expose patterns that enable customers to conduct better carrier sourcing, vetting, and underwriting. By understanding the true movements of a fleet, customers can verify that these patterns match the carrier’s digital footprint. This intelligence ensures that customers know the carriers they are using are real and operating on the roads with the right equipment.

GenLogs uses a three-step privacy filter to ensure that its cameras collect data only on commercial vehicles. The technology deletes any footage of private vehicles before screening for commercial markings, such as a USDOT number, and blurs the vehicle’s windows to prevent biometric person identification.

Beyond diverse commercial applications, GenLogs has worked extensively with both federal and state law enforcement over the last year to combat human trafficking, cargo theft, and narcotics smuggling. In one case, state law enforcement used GenLogs to track a truck engaged in interstate sex trafficking and ultimately recovered a female minor from the truck. In another case, a counter-narcotics agency was able to use GenLogs’ platform to uncover a drug smuggling network and ultimately raid multiple safehouses, resulting in a dozen arrests.

“In a remarkably short time, GenLogs has developed a novel data set of great commercial and prosocial value,” said Marcus Ryu, general partner at Battery Ventures, who will be joining GenLog’s board of directors. “Informed by their intelligence training, Ryan and his co-founders had the insight to recognize that the mission-critical work of multiple industries could be transformed by an incorruptible ground truth of nationwide trucking operations and freight movement.”

For more information, visit www.genlogs.io.

About GenLogs

GenLogs is the Truck Intelligence™ platform leveraging AI on a nationwide network of roadside sensors, satellites, and proprietary datasets. GenLogs tracks all commercial vehicle patterns in the United States in order to drive better business outcomes for customers in trucking, logistics, insurance, commercial real estate, financial institutions, and governments.

SOURCE GenLogs

OAK RIDGE, Tenn., Feb. 3, 2026 — LIS Technologies Inc.‘s (LIST) recently announced laser-based uranium enrichment facility represents a $1.38 billion investment in Oak Ridge, Tennessee, and is expected to create more than 200 jobs in the area. Through its role as Lead Project Integrator, Enveniam will coordinate and lead project management, planning, licensing, design, construction, site readiness, operations readiness and delivery for the facility — the first of its kind in the U.S. and one of the largest nuclear-related investments in Tennessee history.

Alongside Tennessee Gov. Bill Lee, LIST announced its intent to develop the facility on a 206-acre site formerly known as Duct Island and now renamed “LIST Island,” located at the historic K-25 uranium enrichment plant. Enveniam, a BCP portfolio company, brings decades of experience in nuclear engineering and operations and will support LIST as it advances its patented laser isotope separation technology to meet growing demand for domestic enrichment and support U.S. energy and defense needs.

“We are proud to play a key role in this historic investment and to help bring this transformative technology to life,” said Doug Freund, President and CEO of Boston Government Services and Executive Officer of Enveniam. “This project represents a major step forward for U.S. energy independence and nuclear innovation, and we’re honored to support LIST in shaping a more secure and resilient domestic fuel cycle.”

As a trusted Lead Project Integrator for high-stakes, multidisciplinary programs, Enveniam integrates facilities, technology, suppliers and operations from concept through commissioning. Its promise is delivery certainty — cohesive, mission-ready systems that meet requirements and deliver on cost and schedule commitments.

Subject to licensing, permitting and final investment decisions, LIST intends to begin site preparation and construction in 2026, with initial commercial operations targeted before 2030. This announcement follows the company’s selection in the U.S. Department of Energy’s Low-Enriched Uranium (LEU) Enrichment Acquisition Program and further positions Oak Ridge at the forefront of nuclear energy advancement.

For more information on LIS Technologies and this announcement, visit laseristech.com. To learn more about Enveniam and its role in advancing critical energy and infrastructure initiatives, visit enveniamsolutions.com.

About Enveniam

Enveniam advances the nation’s focus on energy dominance and national security through engineering, technology and deep domain expertise. As a Lead Project Integrator, the company delivers integrated solutions across federal and energy markets, including nuclear, oil, natural gas, renewables and critical infrastructure. A BCP portfolio company, Enveniam brings the scale, agility and depth needed to address the world’s most pressing energy and security challenges. For more information, visit enveniamsolutions.com.

Media Contact
Annie Landry
(225) 931-0215
[email protected]

SOURCE Enveniam

• Investment led by Alignment Growth reinforces Kings League’s world-leading position in creator-led sports
• Funding will power international growth through organic expansion and select M&A

BARCELONA, Spain and NEW YORK, Feb. 3, 2026 — Kings League, the creator-led sports competition founded by Gerard Piqué, today announced a $63 million investment round led by Alignment Growth, a U.S.-based media and entertainment investor, with participation from existing shareholders.

Since its launch in Spain in 2023, Kings League has established itself as a global phenomenon in creator-led sports. The brand’s formula – seven-a-side soccer reimagined for the digital age, with teams and competitions led by superstar streamers, content creators and soccer legends including Lamine Yamal, Neymar Jr. and Kaká, and “gamified” rules that guarantee action-packed, unpredictable matches – has driven massive online engagement and redefined how younger generations engage with sport.

The investment will support Kings League’s next phase of growth, aimed at expanding the Kings League and Queens League platforms globally, including launching in the U.S. This follows Kings League’s 2025 launch of new regional leagues in Brazil, France, Germany, Italy and the MENA region, and a new national team World Cup tournament.

Over the course of 2025, Kings League generated 150 million livestreaming hours watched and more than 13 billion impressions across official social channels, consolidating its position as one of the most-watched sports properties on digital platforms globally.

Gerard Piqué, Kings League’s Founder and Chairman – now an entrepreneur following a stellar career in professional soccer with FC Barcelona, Manchester United, and Spain – said: “Kings League has become a global movement, built natively for the digital generation. Alignment Growth brings exceptional media and entertainment experience, and our partnership will help us continue to grow, bring the Kings League experience to new audiences, and explore diversification into new sports.”

Djamel Agaoua, CEO of Kings League, added: “We have proven that our model works at scale. This funding allows us to accelerate our expansion, continue innovating the format and explore strategic M&A opportunities that support our long-term vision. The ambition is clear: to build the leading global platform for creator-led sports and entertainment.”

Kevin Tsujihara, Co-Founder and Managing Partner at Alignment Growth who joined the Board of Kings League, said, “Our investment in Kings League reflects our conviction that digitally native sports properties are uniquely positioned to capture powerful, long-term growth as younger audiences shift how they discover and engage with sports. Gerard, Djamel, and the entire Kings League team have built a truly innovative and global platform combining the world’s most popular sport with a creator-aligned business model and we are thrilled to partner with them on this next phase of expansion.”

To date, Kings League has raised more than $160 million in total funding, supporting its rapid global rollout and the development of an ecosystem that now includes seven regional Kings League men’s competitions, two regional Queens League women’s competitions, and two annual World Cup tournaments, for clubs and national teams. The platform has attracted blue-chip brand partners including adidas, Fortnite, Netflix, Spotify, and Visa, as well as major broadcast and streaming partners such as DAZN and ESPN/Disney+.

About Kings League
Created by football icon and entrepreneur Gerard Piqué, Kings League is a global sports-entertainment phenomenon reimagining the world’s most popular sport for the next generation. Combining elite football with the energy of the creator economy, Kings League blends fast-paced, seven-a-side action with gamified rules inspired by streaming and gaming culture—delivering a format built for modern audiences. Teams are fronted by leading streamers, content creators, and football legends, creating a unique fusion of sport, digital entertainment, and fan-focused storytelling. Since its breakout launch in Spain in 2023, Kings League has grown into a worldwide ecosystem, with competitions established across Brazil, France, Germany, Italy, MENA, Mexico, and Spain. It has expanded into the women’s game with its Queens League competitions and established two annual World Cup international tournaments, for clubs and national teams. For more information, visit https://kingsleague.pro.

About Alignment Growth
Alignment Growth is a private markets specialist investor in the global Media & Entertainment industry, investing behind high-conviction themes and partnering with category-leading companies and entrepreneurs. Our team’s deep industry expertise, operator experience, and direct access to global media, entertainment, tech, and capital markets leaders enable us to identify, access, and unlock differentiated value alongside our partners. For more information, visit: www.alignmentgrowth.com.

Press Contacts:

Kings League
Núria Picas – [email protected] 
Kevin McCullagh – [email protected] 

Alignment Growth
Emily Claffey / Kate Gorgi
FGS Global
[email protected] 

SOURCE Alignment Growth

SAN DIEGO, Feb. 3, 2026 — L’ATTITUDE Ventures, the largest Latino-focused early-stage venture capital firm investing in Latino(a) entrepreneurs, closed 2025 with a strong record of supporting visionary founders and expanding its portfolio impact. Guided by its 2025 theme, “Empowering Visionaries,” the firm demonstrated its ongoing commitment to nurturing innovative businesses and amplifying diverse leadership in venture capital.

Throughout the year, L’ATTITUDE Ventures deployed over $64 million in capital and grew its portfolio to 35 companies, supporting entrepreneurs across technology, AI, fintech, and consumer products. Among the notable investments, AllSpice.io, a San Francisco-based collaboration platform for hardware engineering teams founded by Valentina Ratner and Kyle Dumont received $2.8 million from the firm’s Fund II. The firm also invested $2.5 million into Mapped, an El Segundo, California-based AI-powered platform transforming how data is harnessed across physical spaces. L’ATTITUDE also co-led a $5 million Series A for InOrbit.AI, a Mountain View, California-based robot fleet orchestration platform, and invested $1.5 million in Nibbles, an Austin-based fintech company offering AI-powered pet insurance solutions.

L’ATTITUDE’s portfolio companies achieved significant milestones in 2025. Nopalera, a San Antonio-based multimillion-dollar Latina-owned beauty brand, expanded internationally into Mexico, Australia, and the Middle East. Nopalera and several portfolio companies from New York and California, including Cleverman, Omnitron, and Mavida Health, shared their growth stories at Velocity in Los Angeles during Hispanic Heritage Month, an event designed to accelerate impact and highlight the growing influence of the U.S. Latino consumer cohort.

The firm’s leadership received recognition for its impact on the venture ecosystem and Latino communities. Co-Founder Sol Trujillo was named to the TIME100 Philanthropy List, joining global leaders such as Melinda French Gates, Prince William, and Michael Bloomberg, for his decades-long commitment to advancing Latino economic opportunity. General Partner Laura Moreno Lucas was honored in the Profiles in Diversity Journal 2025 Latino & Hispanic Leadership Awards and published Latinas in VC, a guide spotlighting 31 accomplished female investors and providing strategies, insights, and stories from women breaking into venture capital.

L’ATTITUDE Ventures also strengthened its visibility and industry presence through high-profile events and partnerships. During New York City’s Tech Week, the firm collaborated with Colectivo and Cherryrock Capital to host the Latino VC Leadership Event, spotlighting Latino leadership and fostering discussions on inclusive capital and innovation. The firm concluded its capital deployment period in Q3, shifting focus to driving portfolio growth and creating liquidity for investors while continuing to identify opportunities that align with its mission.

Closing out the year, Trujillo was featured as a speaker at an Axios Live event in early December. During the interview, he discussed the importance of supporting Latino businesses, the shifting U.S. economy, and the role of AI in shaping future opportunity.

“We invest in the fastest-growing segment in the United States—Latino founders,” said Trujillo. “If you want to go where the growth is, you should be investing in these founders.”

About L’ATTITUDE Ventures
With over $100 million in assets under management, L’ATTITUDE Ventures is the largest Latino early-stage venture capital fund investing in technology-first visionary entrepreneurs. The fund provides capital, support, connections, and visibility to empower founders building the next generation of innovative companies.

Led by Co-Founder and Managing Partner Sol Trujillo, and supported by partners Oscar Munoz, Laura Moreno Lucas, and Pete Amaro, the team brings together experienced investors, proven entrepreneurs, and global Fortune 100 executives to create value beyond capital.

For more information, visit https://lattitudeventures.com. 

Media Contact:
Marie Lazzara
JJR Marketing
630-400-3361
[email protected]

SOURCE L’ATTITUDE Ventures

SAN FRANCISCO, Feb. 3, 2026 — Ares Interactive, a game developer and publisher, today announced a $70 million Series A raise led by General Catalyst, with participation from founder and executive chairman Niccolo de Masi. The round represents one of the largest early-stage investments in a game company in recent years and will support Ares Interactive’s vision to build a next-generation, cross-platform free-to-play game company.

Anchored by its studios 7th Inning (San Francisco) and Swift Games (Berlin), Ares pairs veteran game-making expertise with AI-enabled development, marketing, and live-ops workflows. This will allow their teams to iterate faster, scale content efficiently, and respond to player feedback in real time.

Ares Interactive is led by a veteran team of game industry leaders. It’s also supported by an advisory board spanning platforms, publishing, and free-to-play, including Chris Akhavan (former CRO, Glu), Matt Fischer (former VP, Head of Worldwide App Store, Apple), Andrew Stalbow (former CEO, Seriously Digital), and Kent Wakeford (former COO, Kabam).

“This round validates our vision, our approach, and the team behind it,” said Mike DeLaet, President of Ares Interactive. “Ares Interactive brings together rare operating experience and the discipline to build for the long term, as our leadership team has a long history of developing, scaling, and operating hit free-to-play games for some of the most successful publishers in the industry. In a market where many companies are pulling back, this financing gives us the ability to lean in, grow thoughtfully with exceptional partners, and invest in building games we have always wanted to make, creating experiences and communities that will keep players coming back for years to come.”

“We believe Ares Interactive is uniquely positioned to build enduring hit gaming franchises by leveraging the power of AI workflows,” said Erin Schaefer, COO at General Catalyst. “The team combines deep operational experience with a clear creative vision and a disciplined, long-term approach to game development. From our first conversations, it was clear they are building with players at the center, and we’re excited to support them as they scale.”

Ares Interactive is already operating successful live games, led by Heroes vs Hordes, the company’s flagship title, which has surpassed 13 million installs to date. The ultimate survival roguelike RPG has earned strong player ratings and reviews, demonstrating Ares’ focus on polish, fun-first design, and excellence in live operations.

Next up, Ares will launch Baseball Hits 26, a game designed by baseball fans for baseball fans, featuring officially licensed professional baseball players. Additional game announcements are planned for 2026.

[Link to Press Kit] 

About Ares Interactive
Founded in 2024, Ares Interactive is a privately held, next-generation, cross-platform free-to-play game developer and publisher with studios in San Francisco (7th Inning) and Berlin (Swift Games). Built by veteran leaders from some of the most respected names in interactive entertainment, the company brings deep experience shipping, scaling, and operating hit free-to-play games. Ares is focused on creating player-loved experiences designed to grow into long-running franchises and on operating live titles led by its flagship game, Heroes vs Hordes. For more information, visit the Ares Interactive website or LinkedIn.

SOURCE Ares Interactive

CHAPEL HILL, N.C., Feb. 3, 2026 — SonoVascular, Inc., a clinical stage medical device company focused on transforming the treatment of venous thromboembolism (VTE) with its SonoThrombectomy™ System, has completed the first close of its $6 million Series A preferred stock financing. Harbright Ventures, based in Cary, NC, is serving as lead investor, and Robert Ross, Founding Partner at Harbright, has joined SonoVascular’s Board of Directors. The SonoThrombectomy System is an ultrasound facilitated, thrombolytic enhanced thrombectomy system that utilizes microbubble-mediated cavitation as a core mechanism of action. This System is designed to treat blood clots more safely and effectively than today’s thrombectomy solutions and provide a single session, standalone cathlab-based procedure, with maximum clot reduction, and no blood loss or vascular trauma.

SonoVascular has successfully treated ten patients in South America in its First-In-Human (FIH) study for deep vein thrombosis (DVT). Its SonoThrombectomy System achieved a complete 100% Marder score (clot) reduction in all cases as adjudicated by an independent core lab, with no device-related adverse events. Follow-up at both 30-days and 6-months confirmed significant and sustained improvements from baseline in Post-Thrombotic Syndrome (PTS) severity scores, including Villalta, revised Venous Clinical Severity, and Numeric Pain Rating Scale scores. The initial results suggest the SonoThrombectomy System has the potential to redefine how clinicians approach clot management, offering a transformative alternative to today’s standard of care.

Dr. Lisandro Carnero-Vidal, Principal Investigator and Vascular Surgeon at Clínica La Sagrada Familia in Buenos Aires, Argentina, said “There is currently no ideal device for the treatment of deep vein thrombosis, as existing technologies carry inherent trade-offs, including blood loss and risk of valvular or endothelial injury. In this First-In-Human feasibility study, the SonoThrombectomy System demonstrated a favorable safety profile and consistent procedural performance in patients with deep vein thrombosis,” Dr. Carnero-Vidal added, “All ten patients were treated successfully, with no device-related serious adverse events and sustained clinical improvement through six-month follow-up. While these findings are preliminary, they support further clinical evaluation of intravascular sonication as a therapeutic approach intended to preserve venous valves and endothelium without blood loss.”

“SonoVascular has the rare combination of breakthrough technology and the experienced leadership necessary to redefine the standard of care in VTE,” said Robert Ross of Harbright Ventures. “We led this round because SonoVascular is solving the ‘trade-off’ problem that has plagued DVT treatment for years – achieving total clot reduction without the typical risks of blood loss or vessel damage. With exceptionally strong FIH results, we believe this system is well-positioned to become the new standard of care. Equally important, SonoVascular’s solution will ease the burden on ICU capacity, saving hospitals and patients time and money.”

The Series A round will fund achievement of two important milestones during 2026: (i) secure FDA approval for a U.S. based Peripheral Venous pivotal study; and (ii) conduct a FIH study for Pulmonary Embolism treatment. 

The SonoThrombectomy System is intended to provide better outcomes for millions of patients suffering from DVT and pulmonary embolism (PE). DVT is a condition that occurs when blood clots form in the deep veins of the leg, restricting blood flow back to the heart and causing pain and swelling. Additionally, if part of the clot breaks off, it can travel through the bloodstream to the lungs, causing a PE which can be life threatening. To treat these conditions, the SonoThrombectomy System delivers ultrasound energy and microbubbles directly to the clot through the RESONATOR® Catheter, inducing microbubble-mediated cavitation, which mechanically breaks down the clot. A low dose of thrombolytic drug (tPA) is infused in combination with the microbubbles through the catheter to further improve clot treatment. The System is designed to treat DVT and PE more safely and effectively, and at a lower cost to the health care system than currently approved therapies.

About Venous Thromboembolism
As many as 900,000 VTE events occur each year in the United States.¹ One-third to one-half of people who have a DVT will have long-term complications caused by damage to the valves in the vein called post-thrombotic syndrome (PTS).² In some cases, PTS symptoms can be so severe that a person becomes disabled. If part of the clot breaks off, it can travel through the bloodstream to the lungs, causing a pulmonary embolism (PE). PE can be life-threatening, with 10-30% of individuals dying within one month of diagnosis.³

About Harbright Ventures
Harbright Ventures is an early-stage venture capital/private equity firm that focuses on investing in and supporting high-growth, innovative companies across a range of sectors. The firm emphasizes disruptive innovation that can have positive impacts on people and the planet, partnering with entrepreneurs to provide not only capital but strategic guidance and connections to help companies scale. Its investment focus is early-stage and growth opportunities across sectors including medical technology, industrial tech, clean/green technology, and B2B SaaS.

For more information, visit www.harbrightventures.com

About SonoVascular, Inc.
SonoVascular’s SonoThrombectomy™ System is a novel and highly differentiated ultrasound facilitated, thrombolytic enhanced thrombectomy system to treat venous and arterial thrombosis. The system utilizes microbubble-mediated cavitation as a core enabling mechanical mechanism of action to more safely and effectively treat VTE. It is a cathlab-based solution designed to maximize the reduction of clot burden, eliminate blood loss and vascular trauma, and harness the benefit of low dose/duration thrombolytic without bleeding risks. SonoVascular is headquartered in Chapel Hill, NC. The SonoThrombectomy System is an investigational device and has not been cleared or approved by the U.S. Food and Drug Administration. 

Learn more at www.sonovascular.com and follow us on LinkedIn.

Contact:

SonoVascular, Inc.
Daniel Estay
Founder and Chief Executive Officer
[email protected]

¹ Gregson J, Kaptoge S, Bolton T, et al. Cardiovascular Risk Factors Associated With Venous Thromboembolism. JAMA Cardiol. 2019;4(2):163–173. doi:10.1001/jamacardio.2018.4537. 
² Wendelboe AM, Campbell J, McCumber M; Bratzler D; Ding K, Beckman M, Reyes N; Raskob G. The Design and Implementation of a New Surveillance System for Venous Thromboembolism using Combined Active and Passive Methods. American Heart Journal. 2015.
³ American Lung Association; https://www.lung.org/lung-health-diseases/lung-disease-lookup/pulmonary-embolism/learn-about-pulmonary-embolism#:~:text=Pulmonary%20embolism%20affects%20around%20900%2C000,that%20travel%20to%20the%20lungs

SOURCE SonoVascular, Inc.

Funding will accelerate Pasito’s mission to eliminate manual work across insurance and benefits operations, powering carriers, brokers, financial institutions, and employers with AI-native workflows from quote to claim

NEW YORK, Feb. 3, 2026 — Pasito, the AI-native workspace for group health, life, and retirement benefits, today announced it has raised $21 million in Series A funding. The round was led by global software investor Insight Partners, with participation from Y Combinator and insurance-focused MTech Capital.

Pasito is building agentic AI infrastructure that powers the next generation of benefits operations. Its workspace converts unstructured plan and employee census data into a unified data layer, replacing manual plan building and enabling end-to-end automation across sales, quoting, marketing, enrollment, support, and claims.

“Carriers and brokers are buried in operational debt, and employees pay the price through higher costs and fragmented, confusing experiences,” said Pauline Roteta, Founder and CEO of Pasito. “Pasito replaces that broken infrastructure with a centralized AI workspace and agents that automate the hardest work—accurately, transparently, and at scale.”

Pasito’s core AI agents deliver 98% accuracy in plan construction, compared to an industry average of 74%, according to LIMRA, eliminating hundreds of hours of manual work per group. Built on this core agentic layer, Pasito offers pre-configured engagement agents that generate benefits guides, microsites, highlight sheets, personalized recommendations, plan comparisons, sales materials, customer support answers, translations, and omnichannel communications—turning weeks of work into minutes.

The company has seen rapid adoption across the benefits ecosystem. Top customers include carriers such as Reliance Matrix and New York Life, leading consultants like OneDigital and Daybright Financial, as well as retirement advisors and recordkeepers. Over the past year, Pasito has scaled ARR 50x, expanded deployments across thousands of employers, and become a foundational operating platform for some of the largest carriers and brokerages in the U.S.

“Pasito is doing for insurance and group benefits what AI-first companies have done for the legal industry,” said Alexandra Lundin, Vice President at Insight Partners. “They’ve built an AI-native workspace that re-architects how work gets done in an industry that urgently needs modernization. We look forward to partnering with them in this next chapter.”

The new funding will allow Pasito to:

• Invest in engineering to scale its core agentic infrastructure and expand AI automation across additional product lines and workflows
• Grow its forward-deployed teams, working directly with carriers, brokers, employers, and other market participants to automate custom, high-value workflows with AI
• Expand sales and marketing to meet enterprise demand and broaden distribution across the benefits ecosystem

“Pauline and her team are applying AI to automate what has forever been a manual, error-prone process done by insurers and brokers: Producing employee benefits product information and configuring processes — from quoting to claims — for companies’ benefits workflows” said Brian McLoughlin, Partner at MTech Capital. “We’re excited to be part of their team.” 

Over time, Pasito will continue to empower clients to build proprietary AI agents directly within its workspace, launch fully white-labeled experiences, and extend automation across the full benefits lifecycle.

About Pasito

Pasito is the AI-native workspace for group health, life, and retirement benefits. By structuring unstructured insurance and benefits data and powering agentic workflows across the benefits lifecycle, Pasito enables carriers, brokers, financial institutions, and employers to eliminate manual work, improve accuracy, and deliver modern, compliant, and personalized benefits experiences at scale.

About Insight Partners

Insight Partners is a global software investor partnering with high-growth technology, software, and Internet startup and ScaleUp companies that are driving transformative change in their industries. As of June 30, 2025, the firm has over $90B in regulatory assets under management. Insight Partners has invested in more than 875 companies worldwide and has seen over 55 portfolio companies achieve an IPO. Headquartered in New York City, Insight has a global presence with leadership in London, Tel Aviv, and the Bay Area. Insight’s mission is to find, fund, and work successfully with visionary executives, providing them with tailored, hands-on software expertise along their growth journey, from their first investment to IPO. For more information on Insight and all its investments, visit insightpartners.com or follow us on X @insightpartners.

About MTech Capital

MTech Capital is a leading venture capital firm investing in AI-driven companies transforming the insurance and financial services landscape. MTech focuses on early-stage innovation across North America and Europe and is backed by some of the world’s largest insurance companies. Rooted in decades of fintech, venture capital, and insurance investment banking experience, MTech Capital is a hands-on partner for founders looking for unmatched industry networks and expertise.

SOURCE Pasito